PharmaFocus Today – Page 66 – media

Two major pharmaceutical giants collaborate heavily!

On the morning of December 13th, Shiyao Group announced that it has entered into an exclusive authorization agreement with BeiGene for the development, manufacturing, and commercialization of the group’s new methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as any subsequent drugs composed of or containing this compound worldwide. According to the agreement, Shiyao Group will receive a total advance payment of $150 million and has the right to receive up to $135 million in potential development milestone payments and up to $1.55 billion in potential sales milestone payments, as well as tiered sales bonuses calculated based on the annual net sales of the product. Excluding tiered sales commissions, the total amount of the above-mentioned cooperation is as high as 1.835 billion US dollars, which is approximately 13.3 billion yuan at the latest exchange rate. SYH2039 is a clinical candidate drug obtained by Shiyao Group through an AI driven small ...
- Source: drugdu
- 125
- January 3, 2025
$135 million! Domestic liraglutide is coming fiercely

Recently, Hanyu Pharmaceutical announced that its independently developed GLP-1 Liraglutide Injection has been approved by the FDA for marketing as the first generic version and has officially landed in the United States. As we all know, GLP-1 drugs have become the focus of the market in recent years due to their significant efficacy in reducing blood sugar and weight loss. However, precisely because of the skyrocketing demand, this type of drug has repeatedly faced problems of insufficient production and supply. The launch of Hanyu Pharmaceutical’s liraglutide generics in the U.S. market is not only an important breakthrough for Hanyu Pharmaceuticals in the international market, but also marks the imminent release of domestically produced liraglutide generics. Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog that can activate human GLP-1 receptors, promote insulin secretion, inhibit glucagon secretion, delay gastric emptying, and Increases feelings of fullness, thereby lowering blood sugar and weight. Liraglutide ...
- Source: drugdu
- 697
- January 3, 2025
The company is collaborating on multiple vaccine localization production projects with several countries, including Morocco and Indonesia.

According to a report by Daily Economic News, an investor asked on the investor interaction platform: During research inquiries, the company responded that through diversified methods such as technology and equity cooperation, while controlling core cutting-edge technologies, they are helping localities establish independent vaccine production capabilities! Is the company planning to establish joint ventures with foreign partners on-site? Is Watson providing the technology while locals provide the funding? Watson Bio (300142.SZ) stated on the investor interaction platform on December 31 that the company is indeed collaborating on multiple vaccine localization production projects with countries like Morocco and Indonesia. For matters related to the company’s equity cooperation or other significant issues, please refer to the company’s official announcements. https://finance.eastmoney.com/a/202412313283825090.html
- Source: drugdu
- 260
- January 3, 2025
Poly Pharmaceutical Under Investigation, Faces Risk of Forced Delisting

On December 30, Poly Pharmaceutical (300630) announced the progress of the investigation it is under and issued a warning regarding the risks associated with its convertible bond trading. According to the notice from the China Securities Regulatory Commission (CSRC), the company is being investigated due to suspected violations of information disclosure laws and regulations. The company stated in the announcement that if the facts confirmed by the CSRC indicate severe legal violations that warrant forced delisting, the company’s stocks may face the risk of being subjected to significant legal violations resulting in compulsory delisting. Additionally, starting from February 9, 2025, the company’s convertible bonds will enter the repurchase period. During this period, if the company’s stock closes below 70% of the current conversion price for any consecutive thirty trading days, the company may face risks associated with early redemption requests for the principal and interest of the repurchased convertible bonds, ...
- Source: drugdu
- 365
- January 3, 2025
Switching to the Beijing Stock Exchange! The leading fungus detection company plans to go public again

Recently, according to the official website of the Beijing Stock Exchange, the Beijing Stock Exchange Listing Committee is scheduled to hold the 26th review meeting of 2024 at 9:00 am on December 27, 2024. The issuer under review is Dana (Tianjin) Biotech Co., Ltd. (hereinafter referred to as Dana Biotech). It is worth mentioning that at present, the exchanges have not announced the convening of IPO review meetings, and Dana Biotech’s meeting may become the last IPO meeting in 2024. Dana Biotech was founded in 2014 and is mainly committed to the research and development, production and clinical application of early rapid in vitro diagnostic products for invasive fungal diseases (IFD). It is a company that independently provides combined detection solutions and all products for invasive fungal infections. Its R&D team is also very strong. The leader and chief scientist of the R&D team, Zhou Zeqi, is a Ph.D. from ...
- Source: drugdu
- 143
- January 3, 2025
Tirzepatide enters another 10 billion market

Recently, Eli Lilly announced that the FDA has approved Zepbound (tirzepatide) for the new indication of treating moderate to severe obstructive sleep apnea (OSA) in obese people. While using Zepbound, you should reduce your calorie diet and increase physical exercise. The approval of the OSA indication has given Eli Lilly another heavyweight bargaining chip in its competition with its strongest rival Novo Nordisk. Obstructive sleep apnea (OSA) is a respiratory disease in which apnea and/or hypopnea occur repeatedly during sleep. During sleep, the throat and tongue muscles relax, leading to airway obstruction, and air circulation is blocked, causing apnea or weakening of breathing. OSA is common in obese and middle-aged and elderly people, and can cause complications such as coronary atherosclerotic heart disease, heart failure, arrhythmia, and diabetes. Clinical manifestations include snoring, loud snoring, feeling suffocated or waking up at night, and severe cases of cognitive decline and abnormal behavior. ...
- Source: drugdu
- 415
- January 2, 2025
Big news! The first cell-impermeable stent is approved by the FDA for marketing

Recently, Meritone announced that its cell-impermeable stent—Wrapsody was approved by the FDA for marketing. This is the first product approved by the FDA for the treatment of vascular access stenosis or thrombosis in hemodialysis patients. It is reported that Meritone will start commercialization in the United States next year. Founded in 1987, Meritone is a leading medical device manufacturer that produces devices used in cardiac and radiological interventional surgery. Meritone’s product line includes interventional filling devices and accessories, diagnostic and therapeutic catheters and guidewires, disposable pressure monitoring equipment, contrast agent management systems, non-vascular stents, thrombolytic catheters and syringes and needles. The company is committed to meeting the needs of global cardiology and radiology experts through product research and development and high-quality production. Hemodialysis is currently the most widely used blood purification treatment method, suitable for most patients with acute and chronic renal failure. According to statistics and forecasts from Global ...
- Source: drugdu
- 293
- January 2, 2025
Subsidiary’s Drug Clinical Trial Terminated, R&D Investment of 121 Million Yuan

Recently, Tian Tan Bio announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has developed “Intravenous COVID-19 Human Immunoglobulin (pH4)” which is currently in the Phase II clinical trial stage. After a comprehensive evaluation, the company has decided to terminate the Phase II clinical trial and subsequent research and development of the drug. According to the announcement, the total R&D investment for the intravenous COVID-19 human immunoglobulin (pH4) amounts to 121 million yuan, which includes research and development expenses and equipment purchase costs. Among these, the cumulative R&D expenses totaled 117 million yuan, already accounted for in previous fiscal periods, while -0.04 thousand yuan will be accounted for in the 2024 fiscal year. Data shows that Tian Tan Bio’s main business is the research and production of blood products using healthy human plasma or plasma from specifically immunized healthy individuals as raw materials, employing genetic recombination ...
- Source: drugdu
- 103
- January 2, 2025
Lukang Pharmaceutical raises 1.2 billion yuan through private placement to build a high-end intelligent manufacturing workshop for formulations and a biopesticide base

On December 20th, Lu Kang Pharmaceutical announced that the company plans to issue stocks to no more than 35 eligible investors, including the controlling shareholder Hualu Group, with a total fundraising amount of no more than 1.2 billion yuan. After deducting the issuance expenses, the funds will be used for the construction of high-end intelligent manufacturing workshops (total investment 442 million yuan), biopesticide base construction (total investment 432 million yuan), new drug research and development projects (total investment 210 million yuan), and supplementary working capital (200 million yuan). According to the official website, Lu Kang Pharmaceutical is a state-owned comprehensive pharmaceutical enterprise established in 1966. It was listed on the main board of the Shanghai Stock Exchange in 1997 and became a subsidiary of Hualu Holdings Group Co., Ltd. (hereinafter referred to as “Hualu Group”) in 2006. For the 1.2 billion yuan private placement fundraising, Lu Kang Pharmaceutical stated that ...
- Source: drugdu
- 302
- January 1, 2025
Yiming Biotech Completes RMB 200 Million Pre-D Round of Financing

Recently, Jiangsu Yiming Biotechnology Co., Ltd. (hereinafter referred to as “Yiming Biotech”) announced the successful completion of a new round of strategic financing of nearly RMB 200 million. This Pre-D round of financing was jointly invested by Beijing Changping Industrial Development Investment Fund and Beijing Pharmaceutical and Health Industry Investment Fund. It is another round of financing obtained by Yiming Biotech after the C+ round of financing in April 2023. Yiming Biotech said that as a bridge for ATMPs to go global and commercialize, it has been recognized and strongly supported by multiple investors in the current complex market environment. This round of financing will be used to further support the construction of Yiming Biotech’s ATMPs CDMO commercial production base, promote technology iteration, enhance the service capabilities of the CDMO global service network, consolidate the company’s core competitiveness in the ATMPs drug technology track, and create a large CDMO service ...
- Source: drugdu
- 151
- January 1, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.